摘要
目的:观察抗病毒治疗乙型肝炎相关原发性肝癌的疗效。方法:选择2010年6月~2011年6月62例乙型肝炎相关原发性肝癌患者,随机分为两组,对照组31例患者采用常规治疗,观察组31例患者在对照组基础上增加抗病毒药物进行治疗,所有患者均于治疗前与治疗后4周、12周、24周、48周对HBV DNA水平、ALT、AFB进行检查,48周后评价两组患者HBeAg转阴率进行检查。结果:观察组治疗后4周、12周、24周、48周HBV DNA水平、ALT、AFB指标值均低于对照组,两组各时间段比较差异均有统计学意义(P<0.05)。观察组31例患者中HBeAg转阴10例,转阴率为32.26%,对照组无1例HBeAg转阴,两组比较差异具有显著性,有统计学意义(P<0.05)。结论:抗病毒治疗乙型肝炎相关原发性肝癌可明显提高治疗效果,改善患者的肝功能指标,为延长患者的生存期,提高生活质量打下基础。
Objective: To observe the curative effects of antiviral treatment for hepatitis related primary liver cancer.Methods: A total of 62 patients with hepatitis related primary liver cancer that were treated during June 2010 and June 2011 were randomly divided into observation group and control group by half.Both groups were given conventional treatment,while the observation group was also given antiviral treatment.HBV DNA level,ALT,AFB were detected before treatment and 4 weeks,12 weeks and 24 weeks,48 weeks after the treatment.Results: Four weeks,12 weeks and 24 weeks,48 weeks after treatment,HBV DNA level,ALT,AFB indexes were all significant lower than those of the control group(P0.05).Ten out of 31 cases(32.6%) of the observation group showed conversion of positive HBeAg to negative HBeAg,but the negative conversion rate of the control group was 0 showing significant difference between the two groups(P0.05).Conclusion:For patients with hepatitis B related primary liver cancer,the antiviral treatment can improve liver function and prolong patients' life,as well as improve their life quality.
出处
《海南医学院学报》
CAS
2012年第12期1733-1735,共3页
Journal of Hainan Medical University
基金
中国高校医学期刊临床专项资金项目(112210435)~~
关键词
抗病毒
乙型肝炎
原发性肝癌
Antiviral treatment
Hepatitis B related primary liver cancer
Curative effect